butoconazole (Femstat) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Butoconazole, trade names Gynazole-1, an imidazole antifungal used in gynecology for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The exact mechanism of the antifungal action of butoconazole nitrate is unknown; however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.   NCATS

Chemistry

  • SMILES: Clc1ccc(CCC(Cn2ccnc2)Sc3c(Cl)cccc3Cl)cc1
  • InChIKey: SWLMUYACZKCSHZ-UHFFFAOYSA-N
  • Mol. Mass: 411.79
  • ALogP: 6.64
  • ChEMBL Molecules:
    butoconazole  
    butoconazole nitrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$17.9380
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1h-imidazole | 1h-imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, | alant starch | aventis brand of butoconazole nitrate | bayer brand 1 of butoconazole nitrate | bayer brand 2 of butoconazole nitrate | butaconazole | butaconazole nitrate | butoconazol | butoconazole | butoconazole nitrate | butoconazolum | compositenstärke | dahlin | femstal | femstat | femstat 3 | gynazole | gynazole-1 | gynomyk | mycelex-3 | polyfructosanum | rs 35887 | rs-35887 | rs-35887-00-10-3 | syntex brand of butoconazole nitrate | ther-rx brand of butoconazole nitrate | will brand of butoconazole nitrate

Organizations (7)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Candidiasis, Vulvovaginal (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Candidiasis, Vulvovaginal (Phase 2)

Vaginal Diseases (Phase 3)

Vaginitis (Phase 3)

Vulvovaginitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue